MarginsXMarginsX
Home › Markets › Health Care › UPB

Upstream Bio Inc. (UPB)

UPB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.15
-22.66% on the day
Market cap
$117.8M
Micro cap
Revenue · 2025
$2.9M
+20.4% on 2024
Net income · 2025
-$143.4M
-5026.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/0001193125-26-126188-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerUPB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0002022626
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.9M
Net income-$143.4M
Operating income-$160.4M
Net margin-5026.0%
Operating margin-5618.8%
Revenue growth+20.4%
Cash$101.6M
Total assets$353.8M
P/E (computed)Net income was not positive
P/S (computed)41.3×

Warning signs

Cash runway
3.4 months
$47.4M cash at September 30, 2026
Share count, 1 year
+1.4%
2025-11-03 to 2026-11-06
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$105K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Liquidity The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements."
10-Q 2026-11-10
Cash and burn$47.4M cash; operating cash flow -$42.1M a quarter.Report 2026-09-30
Shares outstanding54,811,391 (2026-11-06); 54,038,591 a year earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-03-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $105K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$395K-$41.2M-$54.2M$47.4MNo debt tags$2.9M10-Q 2026-11-10
Q2 2026
2026-06-30
$773K-$39.7M-$35.6M$79.4MNo debt tags$3.2M10-Q 2026-08-11
Q1 2026
2026-03-31
$1.0M-$40.6M-$47.9M$96.7MNo debt tags$3.3M10-Q 2026-05-13
Q4 2025
2025-12-31
$668K-$42.5M-$30.6M$101.6MNo debt tags$2.9M10-K 2026-03-26
Q3 2025
2025-09-30
$683K-$33.7M-$22.2M$72.2MNo debt tags$2.8M10-Q 2026-11-10
Q2 2025
2025-06-30
$937K-$40.0M-$39.2M$45.5MNo debt tags$2.7M10-Q 2026-08-11
Q1 2025
2025-03-31
$566K-$27.3M-$41.2M$71.3MNo debt tags$2.3M10-Q 2026-05-13
Q4 2024
2024-12-31
$613K-$21.2M-$19.6M$325.9MNo debt tags$2.4M10-K 2026-03-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-26
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-16

Source: SEC EDGAR submissions feed, 137 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.9%
1 month-21.7%
3 months-59.8%
Year to date-89.8%
1 year-88.1%
From 52-week high-91.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
IMUXImmunic Inc.$7.23-3.86%$114.8M
SPRBSpruce Biosciences Inc.$42.25-2.45%$121.4M
PDSBPDS Biotechnology Corporation$0.9241+5.90%$113.4M
CATXPerspective Therapeutics Inc.$0.9238-2.05%$111.6M
AKBAAkebia Therapeutics Inc.$0.4486-5.40%$124.6M
OKUROnKure Therapeutics Inc.$2.75+4.56%$111.4M
ALXOALX Oncology Holdings Inc.$1.00-3.85%$124.9M
NERVMinerva Neurosciences Inc$2.20-4.35%$109.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier